Author

M. Kocak

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:clustering· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Approach:machine learning (classical)· 1 Assay:metagenomics· 1

Frequent Co-Authors

J. A. Roth· 2 shared M. G. Rees· 2 shared A. A. Tang· 1 shared A. Bayraktar· 1 shared A. E. Soylu· 1 shared A. G. Berger· 1 shared A. Gundogdu· 1 shared A. Mardinoglu· 1 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

J. A. Roth

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Stratification of the Gut Microbiota Composition Landscape Across the Alzheimer's Disease Continuum in a Turkish Cohort

S. Yildirim, O. U. Nalbantoglu, A. Bayraktar, F. B. Ercan, A. Gundogdu, H. A. Velioglu, M. F. Göl, A. E. Soylu, F. Koc, E. A. Gürpınar, K. S. Kadak, M. Arikan, A. Mardinoglu, M. Kocak, E. Köseoglu, L. Hanoglu

This study identifies distinct gut microbiota community types across Alzheimer's disease stages using machine learning and 16S rRNA sequencing in a Turkish cohort.

bioRxiv · Oct 28, 2021Microbiology

Massively parallel pooled screening reveals genomic determinants of nanoparticle-cell interactions

N. Boehnke, J. P. Straehla, H. C. Safford, M. Kocak, M. G. Rees, M. Ronan, D. Rosenberg, C. H. Adelmann, R. R. Chivukula, N. Nabar, A. G. Berger, N. G. Lamson, J. H. Cheah, H. Li, J. A. Roth, , P. T. Hammond

The paper uses a pooled screening approach to identify genomic factors influencing nanoparticle-cell interactions and validates biomarkers for nanoparticle uptake.

bioRxiv · Apr 5, 2021 · PreprintBioengineering

Non-oncology drugs are a source of previously unappreciated anti-cancer activity

S. M. Corsello, R. T. Nagari, R. D. Spangler, J. Rossen, M. Kocak, J. G. Bryan, R. Humeidi, D. Peck, X. Wu, A. A. Tang, V. M. Wang, S. A. Bender, E. Lemire, R. Narayan, P. Montgomery, , T. R. Golub

The paper identifies non-oncology drugs with anti-cancer activity across 578 cancer cell lines using PRISM, finding that many drugs selectively inhibit cancer cells based on molecular features.

bioRxiv · Aug 9, 2019Cancer Biology